GVAX for Colorectal Cancer
A Pilot Safety Study of Vaccination With Autologous, Lethally Irradiated Colorectal Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor
Doctors at Massachusetts General Hospital seek patients with colorectal cancer with liver metastases to trial therapeutic, autologous (to the self), gene-modified vaccines. The vaccines are cells taken from the patient’s tumor, gene-modified to produce an anti-tumor protein that stimulates the immune system to attack the cancer, then injected back to the patient.
Study participants will receive up to 6 injections of the vaccine after it is made from their tumor cells, then be followed for 2 to 10 years.
- Be 18 years of age or older
- Not have active autoimmune disease
- Be at least 4 weeks since last dose of chemotherapy, radiotherapy, immunotherapy, systemic glucocorticoid therapy or operation in order to receive vaccine
- Not have hepatic metastases involving both branches of the portal vein or all three hepatic veins
THE STUDY INVOLVES:
- Screening to confirm acceptance to the study.
- Recovery of tumor cells and genetic modification in the lab to prepare vaccine therapy.
- Intravenous injections will be scheduled, 6 in total.
- Follow up will continue for 2 to 10 years including physical, lab, and overall survival assessments.
LOCATIONS & CONTACTS:
The study location is at Massachusetts General Hospital in Boston, MA, Map.
Contact: Cristina Ferrone, MD | 6176436189 | [email protected]
Massachusetts General Hospital
Or go online: